Can PSA velocity serve as a surrogate endpoint in trials of hormone-refractory, metastatic prostate cancer? Commentary

John F. Ward

Research output: Contribution to journal › Short survey › peer-review

Fingerprint

Dive into the research topics of 'Can PSA velocity serve as a surrogate endpoint in trials of hormone-refractory, metastatic prostate cancer? Commentary'. Together they form a unique fingerprint.